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 Purpose: Carcinoma of the splenic flexure is uncommon 
and it is associated with a high risk of obstruction. 
However, survival after resection of this tumor is contro-
versial. The aim of this study was to evaluate cancer spe-
cific long-term survival after surgery for splenic flexure 
cancers compared to survival for the colon cancer at other 
sites. 
 Patients and Methods: Of 500 patients undergoing surgery 
for colon cancer, 16 (3.2%) had cancers of the splenic flex-
ure. Clinicopathological features and cancer specific long-
term survival after curative resection were evaluated. 
 Results: Splenic flexure carcinomas were found to be asso-
ciated with a high risk of obstruction (4 out of 16; 25.0%) 
and a high risk of penetration/perforation (1 out of 16; 
6.2%) compared with colon cancers at other sites (P 
<0.0001 and P=0.0128, respectively). Operative mortality 
rate for patients with carcinomas of splenic flexure was 
significantly higher than that of other sites (6.3% versus 
0.8%; P=0.0319). However, resection for splenic flexure tu-
mors was usually possible, and there was no difference in 
cancer specific long-term survival after surgery between 
the patients with splenic flexure cancers and the other site 
colon cancers (P=0.3505). 
 Conclusions: Carcinoma of the splenic flexure has a simi-
lar prognosis to colon cancer at other sites.
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Introduction
 The clinical features of carcinoma of the splenic 
flexure have been elucidated: it is uncommon, 1,1,31 and 
symptoms are often vague and misleading, which may 
be responsible for a delay in diagnosis.2> The incidence 
of obstruction in splenic flexure cancers is approxi-
mately twice that of colon cancers at other sites.',') 
However, survival after resection of splenic flexure 
cancers is controversial. Some authors reported that 
the survival rate of splenic flexure cancers was worse 
than that of other colon cancers"" whereas other stud-
ies have not made any reference to this. 1,2,1) The aim of 
this study was to review our experience with this dis-
ease and to evaluate the cancer specific longterm sur-
vival after surgery for splenic flexure cancers com-
pared to that of colon cancers at other sites.
Methods
 Between January 1982 and December 1997, 500 pa-
tients with a single primary adenocarcinoma of the 
colon underwent surgery at Nagasaki University Hos-
pital. Patients with more than one carcinoma of the 
colon (synchronous or metachronous) were not in-
cluded in the study. The splenic flexure is defined as 
the junction of the distal third of the transverse colon 
with the first part of the descending colon.2 3> In this 
paper, carcinoma of the rectosigmoid junction was con-
sidered with carcinoma of the rectum and patients 
with these cancers were excluded from the study!) 
Colon obstruction was defined in the following situa-
tions: symptoms of increasing constipation, pain and 
vomiting; radiographic signs of abdominal distension 
and abnormal gaseous distension of the gut laparotomy 
findings of proximal bowel distension and edema; and 
urgent surgery performed within 48 hours of admis-
sion. Curative resection was defined as the removal of 
the primary tumor, with or without an anastomosis, 
which was histologically complete, with no metastasis 
to liver, peritoneum or other distant organs. Local re-
currence was defined as convincing evidence of recur-
rence of cancer at the anastomosis, in the abdominal 
wound, in the drain site or peritoneum, but not he-
patic or peritoneal secondaries. Tumor staging was 
classified by Dukes staging, i.e. cancers limited to the 
bowel wall were classified as Dukes' A, those extend-
ing through the wall with negative lymph nodes were 
classified as Dukes' B, cancers with positive lymph 
nodes were defined as Dukes' C, and those with dis-
tant metastasis were classified as Dukes' D.1` 
 Categorical data were analyzed by chi-square or 
Fisher's exact probability test, and continuous data 
were analyzed with a Student's t-test. Analysis of sur-
vival was performed using the method of Kaplan and 
Meier," and differences between the curves were deter-
mined using the log rank test." By this method cases 
were classified as either "Fails" (uncensored data) or 
"Non -fails" (censored data) . Fails were defined as pa-
tients who died due to recurrence of colonic cancer, 
non-fails being surviving patients, or patients who 
died of causes other than cancer of the colon." Patients 
who died within one month of the operation were not
included in the survival analysis. All tests were two-
tailed and a p value of less than 0.05 was considered 
significant.
Results
 500 patients, 16 (3.2%) had carcinomas of the sple-
nic flexure. They included 7 males and 9 females with 
a mean age of 60.7 years (S.D. ± 11.0 years). Table 1 
compares clinical features of splenic flexure cancers 
and colon cancers at other sites. More splenic flexure 
cancers were obstructing than were those occurring at 
other sites (P<0.0001). The splenic flexure cancers 
had perforation and/or penetration induced by the colon 
carcinoma more than the other site colon cancer (P 
=0 .0128). However, there were no significant differ-
ences in age, sex, peritoneal dissemination, hepatic me-
tastasis and extra-abdominal metastasis between the 
two groups (Table 1). 
 Table 2 compares histopathological features of sple-
nic flexure cancers and colon cancers at other sites. 
There were no significant differences in tumor size, 
histologic type, depth of invasion, lymph node metas-
tasis, lymphatic and venous involvement between the 
splenic flexure cancer and the other site colon cancer.
Table 1. Comparison between clinical features in splenic flex-
ure cancers and colon cancers at other sites.
                           No. of Carcinoma (%) 
         Variable Splenic flexure Other sites P value 
                         (n=16) (n=484) 
Age (years)* 60.7±11.0* 65.4±11.9* 0.1231 
Sex 0.2545 
  Male 7(43.7) 281(58.1) 
  Female 9(26.3) 203(41.9) 
Obstruction < 0.0001 
  Absent 12 (75.0) 468(96.7) 
  Present 4(25.0) 16( 3.3) 
Penetration/perforation 0.0128 
  Absent 15(93.8) 481(99.4) 
  Present 1( 6.2) 3( 0.6) 
Peritoneal dissemination 0.4522 
  Absent 15(93.8) 461(92.6) 
  Present 1( 6.2) 23( 7.4) 
Hepatic metastasis 0.1392 
  Absent 14(87.5) 448(89.2) 
  Present 2(12.5) 36(10.8) 
Extra-abdominal metastasis 0.2616 
  Absent 15(93.8) 474(97.9) 
  Present 1( 6.2) 10( 2.1) 
Site of extra-abdominal metastasis 
   Supra-clavicular lymph node 0 3 
  Lung 1 4 
   Bone 0 1 
  Brain 0 0 
  Stomach 0 1 
  Skin 0 1
Table 2. Comparison between histopathological features of 
splenic flexure cancer and colon cancers at other sites.
*Mean ± standard deviation .
                           No. of Carcinoma (%) 
         Variable Splenic flexure Other sites P value 
                         (n=16) (n=484) 
Tumor size (cm)* 4.11±2.01* 4.92±2.37* 0.1775 
Histologic type 0.1370 
  Well differentiated 3(18.8) 148(30.6) 
  Moderately differentiated 13 (81.2) 280(58.0) 
  Poorly differentiated/Mucinous 0( 0 ) 55(11.4) 
Depth of invasion 0.5052 
  Mucosa/ Submucosa/ Muscle layer 3(18.8) 111(23.0) 
  Subserosa 7(43.7) 253(52.4) 
  Serosa exposed/Invasion to 6(37.5) 119(24.6) 
     adjacent organ 
Lymph node metastasis 0.5728 
  Absent 11(68.8) 296(61.8) 
  Present 5(31.2) 183(38.2) 
Lymphatic invasion 0.4515 
  Absent 6(37.5) 138(28.8) 
  Present 10(62.5) 596(71.2) 
Venous invasion 0.3719 
  Absent 10 (62.5) 348(72.7) 
  Present 6(37.5) 131(27.3)
*Mean ± standard deviation .
 Curative resection was performed in 12 of the 16 pa-
tients with splenic flexure cancers. Non-curative resec-
tion was performed in 4 patients (Table 3). Curative re-
section included left hemicolectomy with lymph node 
dissection. There was no difference in a proportion of 
curative resection between the two groups. There was 
also no significant difference in Dukes' stage between 
the two groups (Table 4). 
 Median follow-up was 546 days (range, 112-3775 
days). At the end of the follow-up period (April, 1998), 
393 (78.6%) of the colon cancer patients were alive, 
84 (16.8%) had died from colon cancer, 5 (1.0%) had 
died from operative complications and 18 (3.6%) had
died of causes other than cancer. Operative mortality 
rates for patients with carcinomas of splenic flexure 
and other sites were 6.3% (1 out of 16 patients) and 
in 0.8% (4 out of 484 patients), respectively, which in-
dicated significant difference (P=0.0319). 
 There was no significant difference in cancer spe-
cific long-term survival after surgery between the pa-
tients with splenic flexure cancers and those with can-
cers at other sites (P=0.3505) (Fig. 1). There was also 
no significant difference in survival after curative re-
section between the patients with splenic flexure can-
cers and those with cancers at other sites (P=0.6076) 
(Fig. 2).
Table 3. Comparison between type of operation in splenic 
flexure cancers and colon cancers at other sites.
                         Splenic flexure Other sites p 
value                          (
n=16) (n=484) 
Operation 0.4820 
   Curative 12(75.0) 414(85.5) 
   Non-curative 4(25.0) 69(12.3) 
   Irresectable 0 ( 0 ) 1( 0.2)
Table 4. Comparison of Dukes stage between splenic flexure 
cancers and colon cancers at other sites.
                           No. of Carcinoma (% ) 
                         Splenic flexure Other sites P value
                         (n=16) (n=484) 
Dukes stage 0.5242 
   A 3(18.8) 98(20.3) 
   B 6(37.5) 189(39.1) 
  C 3(18.8) 135(27.9) 
   D 4(25.0) 62(12.8)
Fig. 1. Cancer specific survival in relation to tumor sites in 
patients who underwent surgery. Survival curves indicate 
carcinoma of the splenic flexure (open circles) and other 
sites (closed circles).
Table 5. Comparison of patterns of initial recurrence after 
curative surgery between splenic flexure cancers and colon 
cancers at other sites.
                  Splenic flexure(%) Other sites(%) 
                     (n=11) (n=412) P value 
Recurrence 0.5467 
  No 9(81.8) 362(87.9) 
  Yes 2(18.2) 50(12.1) 
Site of initial recurrence 
   Hematogenous 2(18.2) 28( 6.8) 
   Liver 1 23
   Lung 0 5 
   Spleen 1 0
   Brain 0 1
   Peritoneum 0 9( 2.2) 
  Lymph node 1( 9.1) 7 ( 1.7) 
   Local 0 5 ( 1.2) 
   Unknown 0 4( 1.0)
Fig. 2. Cancer specific survival in relation to tumor sites in 
patients who underwent curative resection. Survival curves 
indicate carcinoma of the splenic flexure (open circles) and 
other sites (closed circles).
Discussion
  In our series 3.2% patients presented colon cancers 
located at the splenic flexure, which is consistent with 
the 2-5% described in other series."' Carcinoma at the 
splenic flexure is associated with the highest risk of 
obstruction. 1-3,11 In our series, the incidence of obstruc-
tion in splenic flexure cancers was approximately eight 
times that of colon cancers at other sites, which is 2-
fold higher than that described in other reports.'-"" In 
this series, there was no significant difference in Dukes' 
stage between splenic flexure cancers and colon can-
cers at other sites. Most authors 1-3) reported that there 
was no significant difference in Dukes staging between 
the two groups. Aldridge et al') reported that the rate 
of curative resection did not vary with tumor site as 
this was constant at approximately 70% at all colon 
sites. Carcinoma of the splenic flexure is often mani-
fested as left upper quadrant or epigastric pain, with 
no abnormal physical findings. Barium enema studies 
in such cases may reveal a tumor of the splenic flexure, 
but special techniques are often necessary for its visu-
alization.') Total colonoscopy is essential for early diag-
nosis of splenic flexure cancers, because of their loca-
tion above the reach of the sigmoidoscope. 
  Survival among patients with splenic flexure cancers 
has been found to be worse than in those with colon 
cancers at other sites3'4' and Aldrige et a13' reported 
that this was the case even in splenic flexure cancers 
without obstruction. However, other studies','," revealed 
that when the tumor site was the splenic flexure sur-
vival was not affected in spite of the high incidence of 
obstruction. It is widely accepted that obstruction in 
large-bowel cancer has some independent effect on sur-
vival.""") In this series, there was no significant differ-
ence in survival between splenic flexure cancers and 
colon cancers at other sites. 
  Extended resection, such as subtotal colectomy or 
extended right hemicolectomy with ileodescending co-
lostomy, might logically be expected to improve sur-
vival of patients with colon cancer at the splenic 
flexure" because the lymph nodes along the course of 
both the superior and inferior mesenteric vessels would 
be removed.') In our series, prognosis of splenic flex-
ure cancers was not worse than in other colon cancers, 
although none of the splenic flexure cancer patients 
underwent the extended resection. In addition, we did 
not observe local recurrence at this site. We thus think 
that dual lymphatic drainage is not disadvantageous 
in terms of survival and that extended resection is un-
necessary." 
 With reference to the report by Aldridge et al,') one 
can pose the question of whether the carcinoma at the
splenic flexure is biologically different from that at 
other sites within the large bowel ? We feel that splen-
ic flexure carcinoma in terms of tumor biology may 
not differ from colon cancers at other sites, because 
there were no differences in modes of metastasis at op-
eration and recurrence between splenic flexure and 
other sites cancers in this series. However, one prob-
lem remains and that is the fact that splenic flexure 
carcinomas carry a high risk of obstruction. The acute 
angle at the splenic flexure may contribute towards 
this risk."") The term 'silent growth' has been applied 
to the splenic flexure carcinoma in the past") as it is 
frequently refractory to diagnosis, often presenting only 
once obstruction has occurred.') Certainly, the present 
study has failed to' identify a clinicopathological rea-
son for increased obstruction at this site. Further ad-
vances in study of the biology of tumors occurring at 
the splenic flexure might help answer this question of 
the high risk of obstruction.
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